

**H.R. 3916, SCREENS for Cancer Act of 2024**

As reported by the House Committee on Energy and Commerce on May 24, 2024

| By Fiscal Year, Millions of Dollars  | 2024 | 2024-2029                                 | 2024-2034 |
|--|------|---|-----------|
| Direct Spending (Outlays)  | 0    | 0   | 0         |
| Revenues   | 0    | 0   | 0         |
| Increase or Decrease (-) in the Deficit  | 0    | 0   | 0         |
| Spending Subject to Appropriation (Outlays)  | 0    | 1,156                                     | 1,375     |
| Increases <i>net direct spending</i> in any of the four consecutive 10-year periods beginning in 2035? | No   | Statutory pay-as-you-go procedures apply? | No        |
|  |      | <b>Mandate Effects</b>                    |           |
| Increases <i>on-budget deficits</i> in any of the four consecutive 10-year periods beginning in 2035?  | No   | Contains intergovernmental mandate?       | No        |
|  |      | Contains private-sector mandate?          | No        |

H.R. 3916 would reauthorize the appropriation of \$275 million each year from 2025 to 2029 for the National Breast and Cervical Cancer Early Detection Program, which is administered by the Centers for Disease Control and Prevention (CDC). Under the program, CDC provides grants to states to support access to screening, diagnosis, and treatment of breast and cervical cancer. The bill also would expand the eligible purposes for those grants and amend the program’s evaluation and reporting requirements. In 2024, CDC allocated \$235.5 million for the program.

Assuming appropriation of the authorized amounts and using historical spending patterns for those activities, CBO estimates that implementing H.R. 3916 would cost \$1.2 billion over the 2024-2029 period and \$219 million after 2029.

See also

[CBO’s Cost Estimates Explained](#), [CBO Describes Its Cost-Estimating Process](#), [Glossary](#)



The costs of the legislation, detailed in Table 1, fall within budget function 550 (health).

**Table 1.**  
**Estimated Increases in Spending Subject to Appropriation Under H.R. 3916**

|                   | By Fiscal Year, Millions of Dollars |      |      |      |      |      | 2024-2029 |
|-------------------|-------------------------------------|------|------|------|------|------|-----------|
|                   | 2024                                | 2025 | 2026 | 2027 | 2028 | 2029 |           |
| Authorization     | 0                                   | 275  | 275  | 275  | 275  | 275  | 1,375     |
| Estimated Outlays | 0                                   | 116  | 239  | 261  | 268  | 272  | 1,156     |

The CBO staff contact for this estimate is Jada Ho. The estimate was reviewed by Sarah Masi, Senior Adviser for Budget Analysis.

Phillip L. Swagel  
Director, Congressional Budget Office